Unlike sarcopenia, which requires both loss of muscle quantity and reduced function, lean mass reduction is a body-composition outcome most often assessed using dual-energy X-ray absorptiometry (DXA) or bioimpedance analysis (BIA) [2, 20]
Without proper oversight, theres a chance of using unapproved versions, incorrect dosages, or missing potential health concerns
Lixisenatide from Zealand Pharma was approved in June 2013, targeting type 2 diabetes
Sodium-glucose transport protein 2 (SGLT2) inhibitors
By mid-2026, a major telehealth platform exited compounded GLP-1 advertising as part of a settlement with Novo Nordisk
GLP-1 receptor agonists stimulate insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning they promote insulin release only when blood glucose levels are elevated